A case of tumor betrayal: Biphasic effects of TIMP-1 on Burkitt's Lymphoma

American Journal of Pathology

Volumn 158, Issue 4, 2001, Pages 1185-1190

  Yan, L ^a   Moses, M A ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME PRECURSOR; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ZINC;

ANGIOGENESIS; APOPTOSIS; BURKITT LYMPHOMA; CANCER STAGING; CANCER THERAPY; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GROWTH RATE; HUMAN; METASTASIS; NOTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR GROWTH; URINALYSIS;

EID: 0035067197     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64067-9     Document Type: Note

References (96)

1. Relating matrix metalloproteinase structure to function: Why the "hemopexin" domain?
2. Cell surface activation of progelatinase A (proMMP-2) and cell migration
3. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin
4. Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines
5. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
6. Molecular characterization and expression of the gene encoding human erythroid-potentiating activity
7. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity
8. Timp-1 is important for epithelial proliferation and branching morphogenesis during mouse mammary development
9. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases
10. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum
11. Tyrosine phosphorylation is crucial for growth signaling by tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2)
12. Recombinant TIMP-1 and -2 enhance the proliferation of rabbit corneal epithelial cells in vitro and the spreading of rabbit corneal epithelium in situ
13. Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism
14. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation
15. Relative expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in mouse renal cell carcinoma cells regulates their metastatic potential
16. Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition
17. The regulation of neovascularization of matrix metalloproteinases and their inhibitors
18. Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1
19. Tissue inhibitor of metalloproteinases-1 (TIMP-1) binds to the cell surface and translocates to the nucleus of human MCF-7 breast carcinoma cells
20. Cell cycle-associated accumulation of tissue inhibitor of metalloproteinases-1 (TIMP-1) in the nuclei of human gingival fibroblasts
21. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1
22. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells
23. Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene
24. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis
25. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells
26. TIMP-3 induces cell death by stabilizing TNF-α receptors on the surface of human colon carcinoma cells
27. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis
28. Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus. Metalloproteinase inhibition is associated with proapoptotic activity
29. p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma
30. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
31. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
32. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model
33. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
34. Cyclic AMP-regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080
35. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2
36. Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma
37. Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4
38. Targeted disruption of the tissue inhibitor of metalloproteinases gene increases the invasive behavior of primitive mesenchymal cells derived from embryonic stem cells in vitro
39. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3
40. Angiogenesis in cancer, vascular, rheumatoid and other disease
41. MMP-9/gelalinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes
42. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
43. Transgenic TIMP-1 inhibits simian virus 40 T antigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and tumor angiogenesis
44. Identification of an inhibitor of neovascularization from cartilage
45. Inhibitors of angiogenesis
46. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase
47. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3
48. Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1
49. Molecular angiogenesis
50. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
51. How does extracellular matrix control capillary morphogenesis?
52. Extracellular matrix as a solid-state regulator in angiogenesis: Identification of new targets for anti-cancer therapy
53. Growth factors in the extracellular matrix
54. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis
55. Neutrophil gelatinase B potentiates interleukin-8 tenfold by amino terminal processing, whereas it degrades CTAP-III, PF-4, and GRO-α and leaves RANTES and MCP-2 intact
56. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1
57. Enhancement of the surface expression of tumor necrosis factor α (TNF-α) but not the p55 TNF-α receptor in the THP-1 monocytic cell line by matrix metalloprotease inhibitors
58. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-α receptors in a human colon adenocarcinoma (Colo 205) cell line
59. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF-α processing in RA synovial membrane cell cultures
60. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3
61. Angiostatin induces and sustains dormancy of human primary tumors in mice
62. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase
63. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance
64. Matrix metalloproteinases generate angiostatin: Effects on neovascularization
65. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3)
66. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9)
67. Elevated matrix metalloprotease and angiostatin levels in integrin α knockout mice cause reduced tumor vascularization
68. The generation of endostatin is mediated by elastase
69. Secreted cathepsin L generates endostatin from collagen XVIII
70. Fibronectin fragments modulate human retinal capillary cell proliferation and migration
71. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo
72. Integrins and anoikis
73. Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells
74. Adhesion-dependent control of matrix metalloproteinase-2 activation in human capillary endothelial cells
75. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5
76. Anti-angiogenic cues from vascular basement membrane collagen
77. Matrix metalloproteinases. Novel targets for directed cancer therapy
78. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer
79. Potential applications of tissue inhibitor of metalloproteinase (TIMP) overexpression for cancer gene therapy
80. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer
81. 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo
82. Urinary type IV collagenase: Elevated levels are associated with bladder transitional cell carcinoma
83. Serum and plasma M(r) 92.000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma
84. Plasma assay of matrix metalloproteinases (MMPs) and MMP-inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment
85. Serum metalloproteinases and their inhibitors: Markers for malignant potential
86. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy
87. Increased incidence of matrix metalloproteinases in urine of cancer patients
88. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer
89. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer
90. High levels of TIMP-2 correlate with adverse prognosis in breast cancer
91. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer - TIMP-1 as a prognostic marker
92. Clinical significance of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in peripheral blood of patients with gastric carcinoma
93. Tissue inhibitor of matrix metallo-proteinase-1 in the plasma of patients with gastric carcinoma. A possible marker for serosal invasion and metastasis
94. Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer
95. Tissue inhibitor of metalloproteinases (TIMP)-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis